Claims
- 1. A method of treating depression, an obsessive compulsive disorder or anxiety in a human in need thereof which comprises administering an effective amount of melatonin receptors (MT-3) agonists: 5-methoxy-carbonylamino-N-acetyltryptamine (5-MCA-NAT) or analogs thereof, the analogs having the following formula I: wherein R is —C(═O)R1, —S(O)2R1 or S(O)R1; R1 is optionally substituted alkyl; optionally substituted alkoxy; optionally substituted aminoalkyl; optionally substituted carbocyclic aryl; an optionally substituted alkylaryl; or an optionally substituted heteroaromatic or heteroalicyclic group having from 1 to 3 rings, 3 to about 8 ring members in each ring and from 1 to about 3 hetero atoms; R2 and R3 are each independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkylthio, optionally substituted alkylsulfonyl, optionally substituted aminoalkyl, optionally substituted carbocyclic aryl, or optionally substituted aralkyl; and pharmaceutically acceptable salts thereof.
- 2. The method of claim 1, wherein said MT-3 agonists are administered by the oral route.
- 3. The method of claim 1, wherein said MT-3 agonists are administered together with an acceptable carrier therefor.
- 4. The method of claim 1, wherein said MT-3 agonists are administered in the form of an orally ingestible capsule or tablet.
- 5. The method of claim 1, wherein said MT-3 agonists are administered in combination with a Ca++ antagonist.
- 6. The method of claim 5, wherein the Ca++ antagonist is nifedipine.
- 7. The method of claim 1, further comprising administration of a serotonin reuptake inhibitor.
- 8. The method of claim 1, further comprising the administration of a tricyclic antidepressant.
- 9. The method of claim 8, wherein the tricyclic antidepressant is bupropion.
CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of U.S. patent application Ser. No. 09/559,609 filed on Apr. 27, 2000, now U.S. Pat. No. 6,239,162, the content of which is relied upon and incorporated by reference in its entirety, and benefit of priority under 35 USC §120 in hereby claimed, which claims the benefit of U.S. Provisional Application No. 60/134,573 filed May 17, 1999.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
6011054 |
Oxenkrug et al. |
Jan 2000 |
A |
6063805 |
Oxenkrug et al. |
May 2000 |
A |
6239162 |
Oxenkrug |
May 2001 |
B1 |
Foreign Referenced Citations (4)
Number |
Date |
Country |
WO 9844796 |
Oct 1998 |
WO |
WO 9844924 |
Oct 1998 |
WO |
WO 9923070 |
May 1999 |
WO |
WO 0012045 |
Mar 2000 |
WO |
Non-Patent Literature Citations (3)
Entry |
E. Molinari, et al., “2-[125I]Iodo-5methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites,” European Journal of Pharmacology, 301: 159-168, 1996. |
E. Molinari, et al., “Localization and Characterization of ML-2 Binding Sites with 2-[125I]-MCA-NAT to CNS and Peripheral Tissues of Various Species,” Society for Neuroscience Abstracts, vol. 20, Abstract No. 479.3, 1994. |
M. Mor, et al., “Medicinal Chemistry Feature Molecule—Guest Editor: Matthew J. Dowd—Melatonin,” Current Medicinal Chemistry, 6:501-518, 1999. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/134573 |
May 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/559609 |
Apr 2000 |
US |
Child |
09/834041 |
|
US |